The enteroinsular axis in dipeptidyl peptidase IV-negative rats

Metabolism: Clinical and Experimental

Volumn 45, Issue 11, 1996, Pages 1335-1341

  Pederson, Raymond A ^a   Kieffer, Timothy J ^b   Pauly, Robert ^b   Kofod, Hans ^b   Kwong, Juliet ^b   McIntosh, Christopher H S ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME INACTIVATION; HORMONAL REGULATION; HORMONE RESPONSE; INSULA; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; RAT;

EID: 0029844706     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90112-2     Document Type: Article

References (45)

1. Mentlein R: Proline residues in the maturation and degradation of peptide hormones and neuropeptides. FEBS Lett 234:251-256, 1988
2. Walter R, Simmons WH, Yoshimoto T: Proline specific endoand exopeptidases. Mol Cell Biochem 30:111-126, 1987
3. Martin RA, Cleary DL, Guido DM, et al: Dipeptidyl peptidase IV (DPP-IV) from pig kidney cleaves analogs of bovine growth hormone-releasing factor (bGRF) modified at position 2 with Ser, Thr, or Val. Extended DPP-IV substrate specificity? Biochim Biophys Acta 1164:252-260, 1993
4. Frohman LA, Downs TR, Williams TC, et al: Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest 78:906-913, 1986
5. Frohman LA, Downs TR, Heimer EP, et al: Dipeptidyl peptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest 83:1533-1540, 1989
6. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, and peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835, 1993
7. Brown JC, Dahl M, Kwauk S, et al: Actions of GIP. Peptides 2:241-245, 1981
8. Moody AJ, Damm Jórgenson K, Thim L: Structure-function relationships in porcine GIF. Diabetologia 21:306, 1981 (abstr)
9. Schmidt WE, Siegel EG, Gallwitz B, et al: Characterization of the insulinotropic activity of fragments derived from gastric inhibitory polypeptide. Diabetologia 29:591A, 1986 (abstr)
10. Adelhorst K, Hedegaard BB, Knudsen LB, et al: Structure-activity studies of glucagon-like peptides-1. J Biol Chem 269:6275-6278, 1994
11. Kieffer TJ, McIntosh CHS, Pederson R: Degradation of glucose-dependent insulinotropic polypeptide (GIP) and truncated glucagon-like peptide 1 (tGLP-1) in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596, 1995
12. Deacon CF, Johnsen AH, Hoist J: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957, 1995
13. Pauly R, Rosche F, Wermann M, et al: Investigation of GIP1-42 and GLP-17-36 degradation in vitro by dipeptidyl peptidase IV (DPIV) using matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOFMS): A novel kinetic approach. J Biol Chem (in press)
14. Watanabe Y, Kojima T, Fujimoto Y: Deficiency of membrane-bound dipeptidylamino-peptidase IV in a certain rat strain. Experientia 43:400-401, 1987
15. Tiruppathi C, Miyamoto Y, Ganapathy J, et al: Genetic evidence for a role of DPIV in intestinal hydrolysis and assimilation of prolyl peptides. Am J Physiol 265:681-689, 1993
16. Matumura C: Dipeptidyl aminopeptidase IV (DAPIV) in urine. Jpn J Pediatr Soc 33:287-291, 1985
17. Pederson RA, Buchan AMJ, Zahedi-Asl S, et al: Effect of jejunoileal bypass in the rat on the enteroinsular axis. Regul Pept 5:53-64, 1982
18. Jia X, Brown JC, Ma P, et al: The effect of glucose dependent insulinotropic polypeptide and glucagon-like peptide 1 (7-36) on insulin secretion. Am J Physiol 268:E645-E651, 1989
19. Drejer K, Kruse V, Larsen UD, et al: Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 40:1488-1495, 1991
20. Morgan LM, Morris BA, Marks V: Radioimmunoassay of gastric inhibitory polypeptide. Ann Clin Biochem 15:172-177, 1978
21. Cataland S, Crockett SE, Brown JC, et al: Gastric inhibitory polypeptide stimulation by oral glucose in man. J Clin Endocrinol Metab 39:223-228, 1974
22. Falko JS, Crockett S, Cataland S, et al: Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. J Clin Endocrinol Metab 41:260-265, 1975
23. Pederson RA, Schubert HE, Brown JC: Gastric inhibitory polypeptide. Its physiologic release and insulinotropic action in the dog. Diabetes 24:1050-1056, 1975
24. Thomas F, Sinar D, Mazzaferri EL, et al: Selective release of gastric inhibitory polypeptide by intraduodenal amino acid perfusion in man. Gastroenterology 74:1261-1265, 1978
25. Kieffer TJ, Buchan AMJ, Barker H, et al: Release of gastric inhibitory polypeptide (GIP) from cultured canine endocrine cells. Am J Physiol 267:E489-E496, 1994
26. Andersen DK, Brown JC, Elahi D, et al: Oral glucose augmentation of insulin secretion: Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. J Clin Invest 62:152-161, 1978
27. Dupre J, Ross SA, Watson D, et al: Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37:826-828, 1973
28. Brown JC, Buchan AMJ, McIntosh CHS, et al: Gastric inhibitory polypeptide, in Schultz SG, Makhlouf GM, Rauner BB (eds): A Handbook of Physiology. Bethesda, MD, American Physiological Society, 1989, pp 403-430
29. Pederson RA: GIP, in Walsh J, Dockray G (eds): Gut Peptides. New York, NY, Raven, 1993, pp 217-259
30. Elahi D, Andersen DK, Brown JC, et al: Pancreatic α- and β-cell response to GIP infusion in normal man. Am J Physiol 237:E185-E191, 1979
31. Pederson RA, Brown JC: The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. Endocrinology 99:780-785, 1976
32. Pederson RA, Schubert HE, Brown JC: The insulinotropic action of "gastric inhibitory polypeptide." Can J Physiol Pharmacol 53:217-223, 1975
33. Kreymann B, Ghatei MA, Williams G, et al: Glucagon-like peptide-1 (7-36): A physiological incretin in man. Lancet 2:1300-1304, 1987
34. Takahashi H, Manaka H, Suda K, et al: Hyperglycaemia but not hyperinsulinaemia prevents the secretion of glucagon-like peptide-1 (7-36 amide) stimulated by fat ingestion. Scand J Clin Lab Invest 51:499-507, 1991
35. Orskov C, Jeppesen J, Madsbad S, et al: Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87:415-423, 1991
36. Orskov C, Rabenhøj L, Wettergren A, et al: Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535-539, 1994
37. Roberge JN, Brubaker PL: Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 133:233-240, 1993
38. Brubaker PL: Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinology 128:3175-3182, 1991
39. Brown JC, Dryburgh JR, Ross SA: Identification and action of gastric inhibitory polypeptide. Recent Prog Horm Res 31:487-532, 1975
40. Sarson DL, Hayter RC, Bloom SR: The pharmacokinetics of porcine glucose-dependent insulinotropic polypeptide (GIP) in man. Eur J Clin Invest 12:457-461, 1982
41. Nauck MA, Schmidt WE, Ebert R, et al: Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: Interactions with glucose, phenylalanine, and cholecystokinin-8. J Clin Endocrinol Metab 69:654-662, 1989
42. Schjoldager BTG, Mortensen PE, Christiansen J, et al: GLP-1 (glucagon-like peptide-1) and truncated GLP-1, fragments of human proglucagon that inhibit gastric acid secretion in humans. Dig Dis Sci 34:703-708, 1989
43. Holst JJ, Orskov C: Glucagon and other proglucagon derived peptides, in Walsh JA, Dockray GJ (eds): Gut Peptides: Comprehensive Endocrinology. New York, NY, Raven, 1994, pp 305-340
44. Bryer-Ash M, Cheung A, Pederson RA: Feedback regulation of glucose-dependent insulinotropic polypeptide (GIF) secretion by insulin in conscious rats. Regul Pept 51:101-109, 1994
45. Fehmann HC, Habener JF: Homologous desensitization of the insulinotropic glucagon-like peptide-1 (7-37) receptor on insulinoma (HIT-T15) cells. Endocrinology 128:2880-2888, 1991